Gitelman´s syndrome as common cause of hypokalemia and hypomagnesemia

Czech version

Authors: Romana Ryšavá ¹; Jana Reiterová ¹; Markéta Urbanová ²; Jitka Štekrová ²; Petr Lněnička ²; Vladimír Tesař ¹
Authors‘ workplace: Nefrologická klinika 1. LF UK a VFN v Praze ¹; Ústav biologie a lékařské genetiky 1. LF UK Praha ²
Published in: Vnitř Lék 2016; 62(Suppl 6): 78-83
Category: Reviews

Overview

The Gitelman syndrome (GS) is an autosomal recessive disorder characterized by hypokalemic metabolic alkalosis and presence of hypocalciuria and hypomagnesemia. It is one of the most common congenital “salt-wasting” tubulopathies, where the impairment of function of the Na⁺-Cl^- cotransporter (NCCT) in the distal convoluted tubule is primary and hypokalemia secondary. Hypomagnesemia is caused by the impairment of magnesium reabsorption through TRPM6 channel which is located just by NCCT. Clinically, patients suffer from fatigue and hypotension due to loss of salt and water and also have cramps and tetany. In some patients chondrocalcinosis can be identified which leads to protracted pain and repeated aseptic inflammations in the joints. The course of the disease, though, is typically benign, and it rarely leads to structural changes in the kidneys or renal impairment. In the period of 2004–2006 we commenced examination of patients with suspected GS based on clinical and laboratory findings within a grant project in the Czech Republic, and in the following years this methodology was introduced to the common laboratory practice. By the year 2011 we had identified 7 different causal mutations in the gene SLC12A3 (4 of them new) among the Czech population, which is responsible for the origin of this disease. The majority of patients, whose clinical findings indicated the presence of GS, had the mutation actually detected, specifically in heterozygous form; 4 individuals were then homozygous. Most of the identified mutations were missense mutations and the most common type found among the Czech population was the change 1315 G>A within the geneSLC12A3, which causes impairment of glycosylation of the NCCT transporter. Further a great number of single-nucleotide polymorphisms were found that may be involved in clinical manifestation of the disease.

Key words:
gene mutation – gene sequence – Gitelman´s syndrome – NCC channel – PCR

Sources

1. Bartter FC, Pronove P, Gill JR et al. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis: a new syndrome. Am J Med 1962; 33: 811–828.

2. Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Transactions Ass Am Phys 1966; 79: 221–235.

3. Shibli AA, Narchi H. Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations. World J Methodol 2015; 5(2): 55–61. Dostupné z DOI: <http://dx.doi.org/10.5662/wjm.v5.i2.55>.

4. Simon DB, Nelson-Willliams C, Bia MJ et al. Gitelman´s variant of Bartter´s syndrome, inherited hypokalemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nature Genetics 1996; 12(1): 24–30.

5. Takeuchi Y, Mishima E, Shima H et al. Exonic mutations in the SLC12A3 gene cause exon skipping and premature termination in Gitelman Syndrome. J Am Soc Nephrol 2014; 26(6): 1–9. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2014030260>.

6. Lin SH, Cheng NL, Hsu YJ et al. Intrafamiliar phenotype variability in patients with Gitelman syndrome having the same mutaitons in their thiazide-sensitive sodium/chloride cotransporter. Am J Kidney Dis 2004; 43(2): 304–312.

7. Wang L, Dong Ch, Xi YG et al. Thiaside-sensitive Na+-Cl- contrasporter: genetic polymorphisms and human diseases. Acta Biochim Biophys Sin 2015; 47(5): 325–334. Dostupné z DOI: <http://dx.doi.org/10.1093/abbs/gmv020>.

8. De Jong JC, Van der Vliet WA, Van den Heuvel L et al. Functional expression of mutations in the human NaCl cotransporter: evidence for impaired routing mechanisms in Gitelman´s syndrome. J Am Soc Nephrol 2002; 13(6): 1442–1448.

9. Peters M, Jeck N, Reinalter S et al. Clinical presentation of genetically deﬁned patients with hypokale- mic salt-losing tubulopathies. Am J Med 2002; 112(3): 183–190.

10. Knoers NVAM, Levtchenko EN. Gitelman syndrome. Orphanet J Rare Dis 2008; 3: 22. Dostupné z DOI: <http://dx.doi.org/10.1186/1750–1172–3-22>.

11. Graziani G, Fedeli C, Moroni L et al. Gitelman syndrome: pathophysiological and clinical aspects. QJM 2010; 103(10): 741–748. Dostupné z DOI: <http://dx.doi.org/10.1093/qjmed/hcq123>.

12. Tosi F, Bianda N, Truttmann AC et al. Normal plasma total magnesium in Gitelman syndrome. Am J Med 2004; 116(8): 573–574.

13. Bianchetti MG, Bettinelli A, Casez JP et al. Evidence for disturbed regulation of calciotropic hormone metabolites in Gitelman syndrome. J Clin Endocrinol Metab 1995; 80(1): 224–228.

14. Nijenhuis T, Vallon V, van der Kemp AW at al. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channels abundance explains thiazide-induced hypocalciuria and hypomagnesemia. Clin Incevt 2005; 115(6): 1651–1658.

15. Cruz DN, Shaer AJ, Bia MJ et al. Yale Gitelman‘s and Bartter‘s Syndrome Collaborative Study Group. Gitelman‘s syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int 2001; 59(2): 710–717.

16. Foglia P, Bettinelli A, Tosetto C et al. Cardiac work up in primary renal hypokalaemia-hypomagnesaemia (Gitelman syndrome). Nephrol Dial Transpl 2004; 19(6): 1398–1402.

17. Chen YC, Yang WC, Yang AH et al. Primary Sjogren´S syndrome associated with Gitelman´s syndrome presenting with muscular paralysis. Am J Kidney Dis 2003; 42(3): 586–590.

18. Moustakakis MN, Bockorny M. Gitelman syndrome and pregnancy. Clin Kidney J 2012; 5(6): 552–555. Dostupné z DOI: <http://dx.doi.org/10.1093/ckj/sfs126>.

19. Blanchard A, Vargas-Poussou R, Vallet M et al. Indomethacin, amiloride, or eplerenone for treating hypokalemia i Gitelman syndrome. J Am Soc Nephrol 2015; 26(2): 468–475. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2014030293>.

20. Urbanová M, Reiterová J, Štekrová J et al. Genetic analysis of Gitelman’s syndrome patients from the Czech republic and Slovakia – Three novel mutations found. Kidney and Blood Press Res 2006; 29(6): 360–365.

21. Urbanová M, Reiterova J, Štektova J et al. DNA analysis of renal electrolyte transporter genes among patients suffering from Bartter and Gitelman syndromes – summary of mutation screening. Folia Biologica (Praha) 2011; 57(2): 65–73.